Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956180 | 0.91 | NPC1 (0.50) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL13490873 | 0.85 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL4142866 | 0.83 | ALDH1A1 (0.58) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL30686627 | 0.83 | ALDH1A1 (0.58) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL22048165 | 0.83 | MAPT (0.58) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL28414075 | 0.82 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL3534158 | 0.82 | RAB9A (0.56) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL31441975 | 0.81 | MAPT (0.42) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL22897608 | 0.81 | MAPT (0.42) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 | |
| SCHEMBL2369186 | 0.81 | ALDH1A1 (0.53) | MAPTSMN1; SMN2RAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620826-B2 | N-phenyl imidazole derivatives; cardiovascular disorders, hypotensive agents, kidney failure | SMITHKLINE BEECHAM CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-20030153567-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20030004202-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| EP-0778833-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0868180-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0778833-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0868180-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-07 | — | — | EP | disclosed |
| WO-1997022341-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-26 | — | — | WO | disclosed |
| EP-0778833-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-18 | — | — | EP | disclosed |
| WO-1996007653-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004202-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | MAPT 3597/4885SMN1; SMN2 4449/4885RAB9A 3524/4885 |
| US-20030153567-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | MAPT 3597/4885SMN1; SMN2 4449/4885RAB9A 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.